Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors

John Chen, Elliott H. Sohn, James C. Folk, Vinit B. Mahajan, Christine N. Kay, H. Culver Boldt, Stephen R. Russell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE: To evaluate whether carbonic anhydrase inhibitors reduce the macular thickness and/or cystic spaces in patients with macular telangiectasia (MacTel) Type 2. METHODS: Retrospective review of patients with nonproliferative cystoid changes associated with MacTel seen at the University of Iowa between 2009 and 2012. Carbonic anhydrase inhibitors were used in 8 patients with MacTel Type 2. Five patients with MacTel Type 2 were observed during this period. Initial and final visual acuities were documented. The presence of cystic spaces and the retinal thickness were measured with spectral-domain optical coherence tomography. RESULTS: Patients treated with oral carbonic anhydrase inhibitors showed significant reduction in both the cystoid cavities and central macular thickness when compared with the patients who were observed (-12.2 μm; P = 0.020). The reduction in retinal thickness was more pronounced in patients receiving acetazolamide (-20.13 μm; P = 0.007) compared with methazolamide (-6.25 μm; P = 0.177). There was no significant change in visual acuity in patients receiving carbonic anhydrase inhibitors. Five patients with MacTel Type 2 did not receive treatment and demonstrated no change in visual acuity, cystoid cavities, or central macular thickness. CONCLUSION: Oral carbonic anhydrase inhibitors, particularly acetazolamide, may decrease macular cystic cavities and reduce central macular thickness but does not appear to improve visual acuity. These findings have yet to be confirmed with a prospective treatment trial.

Original languageEnglish (US)
Pages (from-to)1400-1406
Number of pages7
JournalRetina
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Carbonic Anhydrase Inhibitors
Telangiectasis
Visual Acuity
Acetazolamide
Methazolamide
Optical Coherence Tomography

Keywords

  • acetazolamide
  • carbonic anhydrase inhibitors
  • cystic spaces
  • idiopathic juxtafoveal telangiectasia
  • MacTel Type 2
  • methazolamide

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Chen, J., Sohn, E. H., Folk, J. C., Mahajan, V. B., Kay, C. N., Boldt, H. C., & Russell, S. R. (2014). Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors. Retina, 34(7), 1400-1406. https://doi.org/10.1097/IAE.0000000000000093

Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors. / Chen, John; Sohn, Elliott H.; Folk, James C.; Mahajan, Vinit B.; Kay, Christine N.; Boldt, H. Culver; Russell, Stephen R.

In: Retina, Vol. 34, No. 7, 01.01.2014, p. 1400-1406.

Research output: Contribution to journalArticle

Chen, John ; Sohn, Elliott H. ; Folk, James C. ; Mahajan, Vinit B. ; Kay, Christine N. ; Boldt, H. Culver ; Russell, Stephen R. / Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors. In: Retina. 2014 ; Vol. 34, No. 7. pp. 1400-1406.
@article{987b0705503c4a018a9f328edb24d894,
title = "Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors",
abstract = "PURPOSE: To evaluate whether carbonic anhydrase inhibitors reduce the macular thickness and/or cystic spaces in patients with macular telangiectasia (MacTel) Type 2. METHODS: Retrospective review of patients with nonproliferative cystoid changes associated with MacTel seen at the University of Iowa between 2009 and 2012. Carbonic anhydrase inhibitors were used in 8 patients with MacTel Type 2. Five patients with MacTel Type 2 were observed during this period. Initial and final visual acuities were documented. The presence of cystic spaces and the retinal thickness were measured with spectral-domain optical coherence tomography. RESULTS: Patients treated with oral carbonic anhydrase inhibitors showed significant reduction in both the cystoid cavities and central macular thickness when compared with the patients who were observed (-12.2 μm; P = 0.020). The reduction in retinal thickness was more pronounced in patients receiving acetazolamide (-20.13 μm; P = 0.007) compared with methazolamide (-6.25 μm; P = 0.177). There was no significant change in visual acuity in patients receiving carbonic anhydrase inhibitors. Five patients with MacTel Type 2 did not receive treatment and demonstrated no change in visual acuity, cystoid cavities, or central macular thickness. CONCLUSION: Oral carbonic anhydrase inhibitors, particularly acetazolamide, may decrease macular cystic cavities and reduce central macular thickness but does not appear to improve visual acuity. These findings have yet to be confirmed with a prospective treatment trial.",
keywords = "acetazolamide, carbonic anhydrase inhibitors, cystic spaces, idiopathic juxtafoveal telangiectasia, MacTel Type 2, methazolamide",
author = "John Chen and Sohn, {Elliott H.} and Folk, {James C.} and Mahajan, {Vinit B.} and Kay, {Christine N.} and Boldt, {H. Culver} and Russell, {Stephen R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IAE.0000000000000093",
language = "English (US)",
volume = "34",
pages = "1400--1406",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Decreased macular thickness in nonproliferative macular telangiectasia type 2 with oral carbonic anhydrase inhibitors

AU - Chen, John

AU - Sohn, Elliott H.

AU - Folk, James C.

AU - Mahajan, Vinit B.

AU - Kay, Christine N.

AU - Boldt, H. Culver

AU - Russell, Stephen R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE: To evaluate whether carbonic anhydrase inhibitors reduce the macular thickness and/or cystic spaces in patients with macular telangiectasia (MacTel) Type 2. METHODS: Retrospective review of patients with nonproliferative cystoid changes associated with MacTel seen at the University of Iowa between 2009 and 2012. Carbonic anhydrase inhibitors were used in 8 patients with MacTel Type 2. Five patients with MacTel Type 2 were observed during this period. Initial and final visual acuities were documented. The presence of cystic spaces and the retinal thickness were measured with spectral-domain optical coherence tomography. RESULTS: Patients treated with oral carbonic anhydrase inhibitors showed significant reduction in both the cystoid cavities and central macular thickness when compared with the patients who were observed (-12.2 μm; P = 0.020). The reduction in retinal thickness was more pronounced in patients receiving acetazolamide (-20.13 μm; P = 0.007) compared with methazolamide (-6.25 μm; P = 0.177). There was no significant change in visual acuity in patients receiving carbonic anhydrase inhibitors. Five patients with MacTel Type 2 did not receive treatment and demonstrated no change in visual acuity, cystoid cavities, or central macular thickness. CONCLUSION: Oral carbonic anhydrase inhibitors, particularly acetazolamide, may decrease macular cystic cavities and reduce central macular thickness but does not appear to improve visual acuity. These findings have yet to be confirmed with a prospective treatment trial.

AB - PURPOSE: To evaluate whether carbonic anhydrase inhibitors reduce the macular thickness and/or cystic spaces in patients with macular telangiectasia (MacTel) Type 2. METHODS: Retrospective review of patients with nonproliferative cystoid changes associated with MacTel seen at the University of Iowa between 2009 and 2012. Carbonic anhydrase inhibitors were used in 8 patients with MacTel Type 2. Five patients with MacTel Type 2 were observed during this period. Initial and final visual acuities were documented. The presence of cystic spaces and the retinal thickness were measured with spectral-domain optical coherence tomography. RESULTS: Patients treated with oral carbonic anhydrase inhibitors showed significant reduction in both the cystoid cavities and central macular thickness when compared with the patients who were observed (-12.2 μm; P = 0.020). The reduction in retinal thickness was more pronounced in patients receiving acetazolamide (-20.13 μm; P = 0.007) compared with methazolamide (-6.25 μm; P = 0.177). There was no significant change in visual acuity in patients receiving carbonic anhydrase inhibitors. Five patients with MacTel Type 2 did not receive treatment and demonstrated no change in visual acuity, cystoid cavities, or central macular thickness. CONCLUSION: Oral carbonic anhydrase inhibitors, particularly acetazolamide, may decrease macular cystic cavities and reduce central macular thickness but does not appear to improve visual acuity. These findings have yet to be confirmed with a prospective treatment trial.

KW - acetazolamide

KW - carbonic anhydrase inhibitors

KW - cystic spaces

KW - idiopathic juxtafoveal telangiectasia

KW - MacTel Type 2

KW - methazolamide

UR - http://www.scopus.com/inward/record.url?scp=84903269117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903269117&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000093

DO - 10.1097/IAE.0000000000000093

M3 - Article

C2 - 24451922

AN - SCOPUS:84903269117

VL - 34

SP - 1400

EP - 1406

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -